Literature DB >> 20357779

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.

Renier Brentjens, Raymond Yeh, Yvette Bernal, Isabelle Riviere, Michel Sadelain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20357779      PMCID： PMC2862525          DOI： 10.1038/mt.2010.31

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  6 in total

1.  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

Authors:  John Maher; Renier J Brentjens; Gertrude Gunset; Isabelle Rivière; Michel Sadelain
Journal:  Nat Biotechnol       Date:  2002-01       Impact factor: 54.908

2.  Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Authors:  Daniel Hollyman; Jolanta Stefanski; Mark Przybylowski; Shirley Bartido; Oriana Borquez-Ojeda; Clare Taylor; Raymond Yeh; Vanessa Capacio; Malgorzata Olszewska; James Hosey; Michel Sadelain; Renier J Brentjens; Isabelle Rivière
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

3.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

Authors:  Renier J Brentjens; Jean-Baptiste Latouche; Elmer Santos; Francesc Marti; Michael C Gong; Clay Lyddane; Philip D King; Steven Larson; Mark Weiss; Isabelle Rivière; Michel Sadelain
Journal:  Nat Med       Date:  2003-02-10       Impact factor: 53.440

4.  Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.

Authors:  Renier J Brentjens; Elmer Santos; Yan Nikhamin; Raymond Yeh; Maiko Matsushita; Krista La Perle; Alfonso Quintás-Cardama; Steven M Larson; Michel Sadelain
Journal:  Clin Cancer Res       Date:  2007-09-12       Impact factor: 12.531

Review 5.  The promise and potential pitfalls of chimeric antigen receptors.

Authors:  Michel Sadelain; Renier Brentjens; Isabelle Rivière
Journal:  Curr Opin Immunol       Date:  2009-03-25       Impact factor: 7.486

Review 6.  Targeting tumours with genetically enhanced T lymphocytes.

Authors:  Michel Sadelain; Isabelle Rivière; Renier Brentjens
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716
  6 in total
  177 in total

1.  Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

Authors:  Yangbing Zhao; Edmund Moon; Carmine Carpenito; Chrystal M Paulos; Xiaojun Liu; Andrea L Brennan; Anne Chew; Richard G Carroll; John Scholler; Bruce L Levine; Steven M Albelda; Carl H June
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

Authors:  James N Kochenderfer; Mark E Dudley; Steven A Feldman; Wyndham H Wilson; David E Spaner; Irina Maric; Maryalice Stetler-Stevenson; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; James C Yang; Udai S Kammula; Laura Devillier; Robert Carpenter; Debbie-Ann N Nathan; Richard A Morgan; Carolyn Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

3.  Live and let die: a new suicide gene therapy moves to the clinic.

Authors:  Richard A Morgan
Journal:  Mol Ther       Date:  2012-01       Impact factor: 11.454

Review 4.  Advances in the treatment of metastatic melanoma: adoptive T-cell therapy.

Authors:  Chantale Bernatchez; Laszlo G Radvanyi; Patrick Hwu
Journal:  Semin Oncol       Date:  2012-04       Impact factor: 4.929

5.  Engineered T-cell therapy shows efficacy in blood cancer.

Authors:  Simon Frantz
Journal:  Nat Biotechnol       Date:  2011-10-13       Impact factor: 54.908

6.  Safer CARS.

Authors:  Helen E Heslop
Journal:  Mol Ther       Date:  2010-04       Impact factor: 11.454

Review 7.  Genetic modification of T cells.

Authors:  Chiara Bonini; Malcolm K Brenner; Helen E Heslop; Richard A Morgan
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

Review 8.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 9.  Advances in the development of cancer immunotherapies.

Authors:  Jianjun Gao; Chantale Bernatchez; Padmanee Sharma; Laszlo G Radvanyi; Patrick Hwu
Journal:  Trends Immunol       Date:  2012-09-30       Impact factor: 16.687

Review 10.  Immunotherapy in gastric cancer.

Authors:  Satoko Matsueda; David Y Graham
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.